AzTrials
AzTrials

HeadachePhase 2NCT02866409

Scalp Block Versus Scalp Infiltration With Dexmedetomidine and Local Anesthetic for Post Craniotomy Pain

A Phase 2 study testing scalp block, infiltration and Dexmedetomidine in people with Headache, run by NAVNEH SAMAGH.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study has been designed to assess the efficacy of dexmedetomidine as an adjuvant to local anaesthetic agent bupivacaine in scalp nerve block and scalp infiltration to control post craniotomy pain.A third group where patients were administered bupivacaine only infiltration has also been created. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Headache
What is being tested?
scalp block, infiltration and Dexmedetomidine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
No sites listed yet
Study dates
Nov 2013to Jan 2015
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Neurosurgical patients
  • 18-70 years of age
  • ASA class I and II
  • Patients undergoing elective craniotomy, who were conscious and oriented to time, person and place and able to understand and use Numerical Rating Scale (NRS)

Who cannot join

  • Patient dull and irritable
  • GCS <15
  • Craniotomy incision extending beyond scalp (the field of the block) e.g. craniofacial surgery
  • Patients treated chronically with analgesics or narcotic medications
  • Allergy to local anaesthetics or dexmedetomedine
  • Patients planned for post-operative mechanical ventilation
Show all 11Show fewer
  • Following patients were excluded from the study during collection of data in the postoperative period:-
  • Patients developing fever (≥39°C) in the postoperative period
  • Requiring postoperative ventilation (unplanned)
  • Having poor cognitive function at 1 hour postoperative period
  • GCS <15 in post-operative period.

About this study

Official title: Efficacy of Dexmedetomidine as an Adjuvant to Local Anesthetic Agent in Scalp Block and Scalp Infiltration to Control Post Craniotomy Pain

This study has been designed to assess the efficacy of dexmedetomidine as an adjuvant to local anaesthetic agent bupivacaine in scalp nerve block and scalp infiltration to control post craniotomy pain.A third group where patients were administered bupivacaine only infiltration has also been created.

Read the detailed description

Patients were randomly allocated into three equal groups by computer generated random numbers. For randomization, the simple random allocation rule was followed, wherein the total sample size (n = 150) was randomly divided into three equal groups. In the event of any case has to be excluded because of requirement of postoperative ventilation, altered sensorium or high grade fever in the post-operative period, the same random number code was allocated to the next patient in order to ensure an equal sample size without any modification to the original random number table. The random numbers were then kept in opaque sealed envelopes, numbered sequentially which were opened just before shifting patient inside operation theatre.

The anaesthesiologist who prepared and administered the study drug were not involved in collection of data. The anaesthesiologist who collected the data from the patient in the postoperative period, the operating surgeon and the patient were blinded to the group assigned to the patient.

Pre-operative Assessment:

Pre-operative anaesthetic evaluation was done on the day prior to the surgery. This included a detailed history regarding physical health, any co-morbid illness, current medications, drug allergy and previous anaesthetic experience. The patient was made familiar about the NRS (0-10, with 0 = no pain, 10 = worst pain ever). A written and informed consent was taken. Patients were fasted and premedicated according to the departmental protocol.

Duration of study period-

Study period started after closure of skin incision of the scalp and continued till 48 hours in the postoperative period

Study groups-

Patients were randomly divided into three groups:

Group BI - Bupivacaine infiltration around surgical incision.

Group BDI - Bupivacaine and dexmedetomidine infiltration around surgical incision

Group BDNB- Bupivacaine and dexmedetomidine used in scalp nerve block.

Anaesthesia Technique-

A standard anaesthesia technique according to the departmental protocol was followed in all the patients. Pre-induction monitoring (Datex- Ohmeda S/5 Avance, Madison, WI, USA) consisted of 5-lead electrocardiography, heart rate, automated non-invasive blood pressure, and pulse oximetry. The patients were then be induced with propofol (1-2 mg/kg) or thiopentone (4-6mg/kg) and trachea were intubated with vecuronium 0.1 mg/kg. Anaesthesia was maintained with intravenous (propofol) or inhalational (isoflurane/sevoflurane/desflurane) anaesthetic agent along with nitrous oxide-oxygen mixture (60:40) and intermittent doses of intravenous vecuronium (0.02 mg/kg). Ventilation was maintained at ETCO2 30 to 35mm Hg. Total fresh gas flow rate was kept at 1-2 L/min. A radial artery catheter was inserted for continuous blood pressure monitoring and blood sampling if indicated. Intraoperative analgesia was maintained with intravenous morphine 0.1mg/kg and morphine repeated at a dose of 0.05 mg/kg if duration of surgery was more than 3 hours. Patients were reversed with neostigmine (0.05mg/kg) and glycopyrolate (0.01mg/kg) after administration of study drugs and were extubated once patient started responding to verbal commands and able to generate adequate tidal volume under spontaneous respiration.

Methods of postoperative analgesia- In all the patients, analgesic procedure was done ensuring proper aseptic precaution at the end of the surgery, after closure of skin incision and before putting the dressings over the incision. Patients were reversed from anaesthesia after the administration of study drugs.

Group BI: The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.

Group BDI: The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.

Group BDNB: Scalp nerve blocks were given with15-20 ml of combination of Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept less than 2 mg /kg.

In this group following nerves were blocked-

  1. Supra-orbital nerve
  2. Supra-trochlear nerve
  3. Zygomatico-temporal nerve
  4. Auriculo-temporal nerve
  5. Posterior auricular branches of the greater auricular Nerve
  6. The greater, lesser, and third occipital nerves

Post-operative assessment:

After extubation patients were shifted to the Post anaesthesia care unit (PACU) and assessed for haemodynamic parameters, sedation and any complication at 15 minutes interval till 2hrs and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours. Assessed for cognitive function at 30 min and 60 min.

Patients were followed after discharge for 6 months by telephonic communication at 1, and 3 month interval for presence of chronic pain.

COLLECTION OF DATA-

Preoperative- Age, sex, weight, ASA status, diagnosis, surgery

Intraoperative-

  1. Site of incision
  2. Duration of surgery
  3. Intra-operative analgesia- morphine in mg/kg

Postoperative-

  1. Haemodynamic parameters- Heart rate, systolic and diastolic blood pressure, oxygen saturation was recorded at arrival to PACU and every 15 min interval for 2 hours. Then heart rate and systolic and diastolic blood pressure at 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.
  2. Respiration rate-was recorded at arrival to PACU and every 15 min interval for 2 hours and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.
  3. Cognitive function- Patients were evaluated for cognitive function 30 minutes after shifting to PACU using a modified self-devised questionnaire of short orientation memory concentration test. Whenever the subjects were able to recall and count with minimal mistakes (1 to 3), were regarded as good, with more than 3 mistakes as fair, and if not be able to recall at all, it was regarded as poor. If the cognitive function outcome was poor then same test was repeated at 1 hour after shifting to PACU. If outcome was again poor, then that patient was excluded from the study.
  4. Assessment of pain- Postoperative pain was assessed by Numerical rating scale (NRS) where in 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain'. It was assessed at arrival to PACU and at 0, 0.5, 1, 1.5, 2, 4, 8, 12, 16, 20, 24, 36 and 48 hours after surgery.
  5. Pain free period- Time of first rescue analgesic administration from the time of test drug administration was recorded.
  6. Postoperatively rescue analgesic- When NRS score was ≥ 4, rescue analgesic paracetamol 1gm was administered intravenously and total rescue analgesic requirement in 24 and 48 hrs were noted.
  7. Rescue drugs to maintain haemodynamic stability- Any adverse events like bradycardia (Heart rate ≤ 40), hypotension (SBP < 90 mm of Hg) were recorded and treated by rescue drugs: atropine-15µg/Kg and mephenteramine-3mg/dose respectively. Total amount of rescue drug requirement in 24 and 48 hours were noted.
  8. Postoperative sedation- Level of sedation was assessed using Modified Ramsay Sedation Scale.
  9. Adverse events-
  10. Respiratory depressions (Respiration rate < 8 breaths/min) was recorded and managed accordingly.
  11. Postoperative nausea and vomiting (PONV) was assessed on a 4-point scale. and was treated with ondansetron 0.15 mg/kg intravenously if score was >2.
Conditions
Headache
Being tested
scalp block, infiltration, Dexmedetomidine, Bupivacaine
Keywords
dexmedetomidine, nerve block, anesthesia infiltration
Medical subject headings
Headache

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • scalp blockProcedure or surgery

    In this group following nerves were blocked-

    1. Supra-orbital nerve
    2. Supra-trochlear nerve
    3. Zygomatico-temporal nerve
    4. Auriculo-temporal nerve
    5. Posterior auricular branches of the greater auricular Nerve
    6. The greater, lesser, and third occipital nerves
  • infiltrationProcedure or surgery

    The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.

  • DexmedetomidineDrug

    Also called Precedex, Dexdor

    Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.

  • BupivacaineDrug

    Also called Marcaine, Sensorcaine, Marcain

    20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration

Study groups in NCT02866409
Study groupRoleWhat they receive
Bupivacaine,dexmedetomidine scalp blockExperimentalBupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
Receives: Procedure: scalp block; Drug: Dexmedetomidine; Drug: Bupivacaine
bupivacaine dexmedetomidine infiltrationActive comparatorThe incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
Receives: Procedure: infiltration; Drug: Dexmedetomidine; Drug: Bupivacaine
bupivacaine infiltrationActive comparatorThe incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
Receives: Procedure: infiltration; Drug: Bupivacaine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. post craniotomy pain by Numerical rating scale (NRS)

    Numerical rating scale (NRS) is a scale from 0 to 10 where 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain

    Measured: Immediately after extubation

  2. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 30 minutes after extubation

  3. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 1 hour after extubation

  4. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 1.5 hours after extubation

  5. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 2 hours after extubation

  6. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 4 hours post extubation

  7. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 8 hours post extubation

  8. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 12 hours post extubation

  9. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 16 hours post extubation

  10. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 20 hours post extubation

  11. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 24 hours post extubation

  12. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 36 hours post extubation

  13. post craniotomy pain by Numerical rating scale (NRS)

    Measured: 48 hours post extubation

Secondary outcomes (13)
  1. chronic pain using Numerical rating scale (NRS)

    Numerical rating scale (NRS) is a scale from 0 to 10 where 0 shows 'no pain' and 10 shows 'worst imaginable excruciating pain

    Measured: 1 month

  2. chronic pain using Numerical rating scale (NRS)

    Measured: 3 months

  3. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 15 minutes interval till 2hrs post extubation and then at 4, 8, 12, 16, 20, 24, 36 and 48 hours.

  4. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 4 hours

  5. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 8 hours.

  6. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 12 hours.

  7. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 16 hours.

  8. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 20 hours.

  9. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 24 hours.

  10. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 36 hours.

  11. post operative sedation using Modified Ramsay Sedation Scale

    Sedation Score-- by Modified Ramsay Sedation Scale

    1. Anxious/ Agitated/ Restless
    2. Cooperative/ Oriented/ Tranquil
    3. Responds to verbal commands
    4. Brisk response to light glabellar tap or loud noise
    5. Sluggish response to light glabellar tap or loud noise
    6. No Response

    Measured: 48 hours.

  12. rescue analgesic requirement in grams

    total rescue analgesic requirement in grams of paracetamol consumed in 24 hours

    Measured: 24 hrs

  13. rescue analgesic requirement in grams

    total rescue analgesic requirement in grams of paracetamol consumed in 48 hours

    Measured: 48 hrs

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2016 (estimated)
  2. Study startNov 2013
  3. Primary completionDec 2014
  4. Study completionJan 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
150 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02866409
Sponsor's protocol ID
NK/1062/MD/13422-423
Status last verified
Aug 2016
First submitted
3 Aug 2016
Last updated
15 Aug 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing scalp block, infiltration and Dexmedetomidine in people with Headache, run by NAVNEH SAMAGH.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

post craniotomy pain by Numerical rating scale (NRS) (time frame: Immediately after extubation). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in